ASTRO 2022 | SALV-ENZA: SRT plus enzalutamide for PSA recurrent high-risk prostate cancer delays PSA progression

Phuoc Tran, MD, PhD, University of Maryland, MD, shares the results of the Phase II SALV-ENZA (NCT02203695) trial investigating of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy. A total of 86 patients were randomized with a median follow-up of 34 (range 0-52) months. The primary endpoint was freedom from PSA progression. Freedom from PSA progression was significantly improved with enzalutamide versus placebo. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.